Skip to content

Study on the Application of Peripheral Blood Circulating Tumor Cells in Early Diagnosis, Treatment and Prognostic Evaluation of Gastric Cancer

Study on the Application of Peripheral Blood Circulating Tumor Cells in Early Diagnosis, Treatment and Prognostic Evaluation of Gastric Cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000031049
Enrollment
Unknown
Registered
2020-03-21
Start date
2020-03-20
Completion date
Unknown
Last updated
2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Gold Standard:Pathological examination
Blood&#32
Tumor&#32

Sponsors

The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria of the experimental group: 1. Patients with gastric adenocarcinoma diagnosed before operation; 2. Fully informed before operation; 3. All patients undergo laparoscopic radical gastrectomy and postoperative chemotherapy with FOLFOX6 regimen. The inclusion criteria of the control group: 1. In the same period, patients with benign lesions were confirmed by pathology (including chronic inflammation, benign ulcer, hemorrhage, etc.); 2. There are no significant differences in age and sex between patients with benign gastric tumor and patients with gastric cancer.

Exclusion criteria

Exclusion criteria: Exclusion criteria of the experimental group: 1. Received antineoplastic therapy before operation; 2. Loss of follow-up patients. Exclusion criteria of the control group: Have a history of tumor in the past.

Design outcomes

Primary

MeasureTime frame
circulating tumor cells(CTCs);SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactHongbin Liu

The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army

liuhongbin999@163.com+86 931-8994364

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026